Analysis of clinical features and outcome of 356 triple-negative breast cancer patients in China

Breast Care

Volumn 7, Issue 1, 2012, Pages 13-17

  Zhang, Li ^a   Hao, Chunfang ^a   Dong, Guolei ^a   Tong, Zhongsheng ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Multivariate analysis; Triple negative breast cancer: clinical features prognosis

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84863338416     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000336539     Document Type: Article

References (25)

1. Kinne DW, Butler JA, Kimmel M, et al.: Estrogen receptor protein of breast cancer in patients with positive nodes: high recurrence rates in the postmenopausal estrogen receptor-negative group. Arch Surg 1987;122:1303-1306. (Pubitemid 18021287)
2. Parl FF, Schmidt BP, Dupont WD, et al.: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984;54:2237-2242. (Pubitemid 15210812)
3. Pichon MF, Broet P, Magdelenat H, et al.: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996;73:1545-1551. (Pubitemid 26235381)
4. Dent R, Trudeau M, Pritchard KI, et al.: Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434. (Pubitemid 47219710)
5. Rakha EA, El Sayed ME, Green AR: Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25.
6. Nielsen TO, Hsu FD, Jensen K, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374. (Pubitemid 39100473)
7. Banerjee S, Reis-Filho JS, Ashley S, et al.: Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729-735. (Pubitemid 44048783)
8. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, et al.: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007;7:203.
9. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-244. (Pubitemid 46291713)
10. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334. (Pubitemid 46698581)
11. Rhee J, Han SW, Oh DY, et al.: The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008;8:307.
12. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
13. Yuan ZY, Wang SS, Gao Y, et al. Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases. Ai Zheng 2008;27:561-565.
14. Mersin H, Yildirim E, Berberoglu U, Gülben K: The prognostic importance of triple negative breast carcinoma. Breast 2008;17:341-346.
15. Brown M, Tsodikov A, et al.: The role of human epidermal growth factor receptor-2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 2008;112:737-747. (Pubitemid 351240567)
16. Field TS, Buist DS, Doubeni C, et al.: Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr 2005;35:88-95.
17. Joslyn SA: Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002;73:45-59. (Pubitemid 34548165)
18. Kroger N, Milde-Langosch K, Riethdorf S, et al.: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006;12:159-168. (Pubitemid 43166190)
19. Rouzier R, Perou CM, Symmans WF, et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685. (Pubitemid 41170290)
20. Siziopikou KP, Cobleigh M: The basal subtype of breast carcinomas may rep resent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007;16:104-107. (Pubitemid 46172864)
21. O'Shaughnessy J, Osborne C, Pippen J, et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol (meet abstr) 2009;27:15S.
22. Bauer KR, Brown M, Cress RD, et al.: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:l721-728.
23. Cleator S, Heller WR, Coombes C: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-244. (Pubitemid 46291713)
24. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI: Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103:2241-2251. (Pubitemid 40686567)
25. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol 2006;24:5652-5657. (Pubitemid 46631305)